| 31. |
|
|
| 32. |
|
|
| 33. |
- Edsjö, Anders, et al.
(author)
-
Molekylär patologi : nyckeln till målinriktad cancerbehandling [Molecular pathology - the key to precision oncology]
- 2021
-
In: Läkartidningen. - : Läkartidningen Förlag AB. - 0023-7205 .- 1652-7518. ; 118
-
Journal article (peer-reviewed)abstract
- Rapidly expanding knowledge of the molecular landscape of cancers has resulted in the implementation of an increasing number of specific therapies targeted at tumors with specific molecular aberrations. In response to this development, new tools for predictive testing for molecular targets need to be implemented in routine health care. To achieve robust future molecular diagnostic pathology, and equal opportunity for patients to qualify for targeted therapy, the national working group for Solid Tumors in the initiative Genomic Medicine Sweden (GMS) aims to implement regional and national platforms for comprehensive genomic tumor profiling and linked analysis pipelines. Novel IT-infrastrucutures and recruitment of bioinformaticians and molecular biologists to hospital labotatories are paramount. The infrastructure will allow wider inclusion into clinical trials and supplement the national cancer registries with molecular »real world data« for research and evaluation of implemented cancer therapies and diagnostic procedures.
|
|
| 34. |
- Edsjö, Anders, et al.
(author)
-
Molekylär patologi – nyckeln till målinriktad cancerbehandling
- 2021
-
In: Lakartidningen. - : Läkartidningen Förlag AB. - 0023-7205 .- 1652-7518. ; 118
-
Journal article (peer-reviewed)abstract
- Rapidly expanding knowledge of the molecular landscape of cancers has resulted in the implementation of an increasing number of specific therapies targeted at tumors with specific molecular aberrations. In response to this development, new tools for predictive testing for molecular targets need to be implemented in routine health care. To achieve robust future molecular diagnostic pathology, and equal opportunity for patients to qualify for targeted therapy, the national working group for Solid Tumors in the initiative Genomic Medicine Sweden (GMS) aims to implement regional and national platforms for comprehensive genomic tumor profiling and linked analysis pipelines. Novel IT-infrastrucutures and recruitment of bioinformaticians and molecular biologists to hospital labotatories are paramount. The infrastructure will allow wider inclusion into clinical trials and supplement the national cancer registries with molecular »real world data« for research and evaluation of implemented cancer therapies and diagnostic procedures.
|
|
| 35. |
- Edsjö, Anders, et al.
(author)
-
Molekylär patologi – nyckeln tillmålinriktad cancerbehandling : Heltäckande molekylär tumörkarakterisering ger möjlighetatt undersöka samtliga behandlingsalternativ med en analys [Molecular pathology - the key to precision oncology]
- 2021
-
In: Läkartidningen. - : Sveriges Läkarförbund. - 0023-7205 .- 1652-7518. ; 118
-
Research review (peer-reviewed)abstract
- Rapidly expanding knowledge of the molecular landscape of cancers has resulted in the implementation of an increasing number of specific therapies targeted at tumors with specific molecular aberrations. In response to this development, new tools for predictive testing for molecular targets need to be implemented in routine health care. To achieve robust future molecular diagnostic pathology, and equal opportunity for patients to qualify for targeted therapy, the national working group for Solid Tumors in the initiative Genomic Medicine Sweden (GMS) aims to implement regional and national platforms for comprehensive genomic tumor profiling and linked analysis pipelines. Novel IT-infrastrucutures and recruitment of bioinformaticians and molecular biologists to hospital labotatories are paramount. The infrastructure will allow wider inclusion into clinical trials and supplement the national cancer registries with molecular »real world data« for research and evaluation of implemented cancer therapies and diagnostic procedures.
|
|
| 36. |
- Ekberg, Anders, 1967, et al.
(author)
-
Identifying the root causes of damage on the wheels of heavy haul locomotives and its mitigation
- 2014
-
In: Proceedings of the Institution of Mechanical Engineers, Part F: Journal of Rail and Rapid Transit. - : SAGE Publications. - 0954-4097 .- 2041-3017. ; 228:6, s. 663-672
-
Journal article (peer-reviewed)abstract
- The paper illustrates how damage patterns in the form of rolling contact fatigue (RCF) on wheels, can be employed to identify and improve underlying operational conditions. The focus is on RCF of locomotive wheels operating on the Iron Ore Line in northern Sweden and Norway. Seasonal changes and damage patterns are charted. Potential root causes for observed damage patterns are identified and investigated. Mitigating actions are proposed and the efficiency of implemented actions is quantified.
|
|
| 37. |
- Ekberg, Anders, 1967, et al.
(author)
-
Identifying the root causes of damage on the wheels of heavy haul wheel damage phenomena
- 2013
-
In: Proceedings of the 10th International Heavy Haul Conference (IHHA 2013), February 4–6, New Dehli, India. ; , s. 520-526
-
Conference paper (peer-reviewed)abstract
- The paper illustrates how damage patterns, in particular in the form of rolling contact fatigue (RCF), can be employed to identify underlying operational conditions. In particular the focus is on RCF of wheel occurring at the Iron Ore line in north Sweden and Norway. The paper charts seasonal changes and damage patterns, and potential root causes are identified and investigated. Finally mitigating actions are proposed.
|
|
| 38. |
- Eklund, Anders, et al.
(author)
-
A Bayesian Heteroscedastic GLM with Application to fMRI Data with Motion Spikes
- 2017
-
In: NeuroImage. - : Elsevier. - 1053-8119 .- 1095-9572. ; 155, s. 354-369
-
Journal article (peer-reviewed)abstract
- We propose a voxel-wise general linear model with autoregressive noise and heteroscedastic noise innovations (GLMH) for analyzing functional magnetic resonance imaging (fMRI) data. The model is analyzed from a Bayesian perspective and has the benefit of automatically down-weighting time points close to motion spikes in a data-driven manner. We develop a highly efficient Markov Chain Monte Carlo (MCMC) algorithm that allows for Bayesian variable selection among the regressors to model both the mean (i.e., the design matrix) and variance. This makes it possible to include a broad range of explanatory variables in both the mean and variance (e.g., time trends, activation stimuli, head motion parameters and their temporal derivatives), and to compute the posterior probability of inclusion from the MCMC output. Variable selection is also applied to the lags in the autoregressive noise process, making it possible to infer the lag order from the data simultaneously with all other model parameters. We use both simulated data and real fMRI data from OpenfMRI to illustrate the importance of proper modeling of heteroscedasticity in fMRI data analysis. Our results show that the GLMH tends to detect more brain activity, compared to its homoscedastic counterpart, by allowing the variance to change over time depending on the degree of head motion.
|
|
| 39. |
|
|
| 40. |
- Eltahir, Mohamed, et al.
(author)
-
An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
- 2022
-
In: Advanced Therapeutics. - : Wiley. - 2366-3987. ; 5:7
-
Journal article (peer-reviewed)abstract
- The agonistic potentials of therapeutic anti-CD40 antibodies have been profiled in relation to antibody isotype and epitope specificity. Still, clinical impact relies on a well-balanced clinical efficacy versus target-mediated toxicity. As CD40-mediated immune activation must rely on a combination of stimulation of antigen-presenting cells (APCs) alongside antigen presentation, for efficient T cell priming, alternative approaches to improve the therapeutic outcome of CD40-targeting strategies should focus on providing optimal antigen presentation together with CD40 stimulation. Herein, a bispecific antibody targeting CD40 as a means to deliver cargo (i.e., synthetic peptides) into APCs through a non-covalent, high-affinity interaction between the antibody and the cargo peptide, further referred to as the Adaptable Drug Affinity Conjugate (ADAC) technology, has been developed. The ADAC platform demonstrated a target-specific CD4+ and CD8+ T cell expansion in vitro and significantly improved peptide-specific CD8+ T cell proliferation in vivo. In addition, the strategy dramatically improved the in vitro and in vivo half-life of the synthetic peptides. Future applications of ADAC involve pandemic preparedness to viral genetic drift as well as neoepitope vaccination strategies where the bispecific antibody is an off-the-shelf product, and the peptide antigen is synthesized based on next-generation sequencing data mining.
|
|
